Brolucizumab is a humanized monoclonal single-chain Fv (scFv) antibody fragment with a molecular weight of ~26 kDa, produced in Escherichia coli cells by recombinant DNA technology.
One mL solution for injection contains 120 mg of brolucizumab.
Each vial contains 27.6 mg of brolucizumab in 0.23 mL solution. This provides a usable amount to deliver a single dose of 0.05 mL containing 6 mg of brolucizumab.
Excipients/Inactive Ingredients: 10 mM sodium citrate, 5.8% sucrose, 0.02% polysorbate 80 and water for injection and has a pH of approximately 7.2.